New Drug, SEP‑363856, Shows Promise in Helping with Parkinson’s Disease Psychosis
Our Director, Dr. Stuart Isaacson, was quoted in a story by Parkinson’s News Today about a new drug candidate for Parkinson’s disease Psychosis, also referrred to as PDD. Click Here to read more or read our other blog post news articles for more information.
“We sought out, in this trial, to use a proof-of-principle study to evaluate the efficacy and safety of SEP-363856 in patients with Parkinson’s disease psychosis,” said Stuart Isaacson, MD, medical director of the Parkinson’s & Alzheimer’s Research and Education Foundation, who presented the trial’s results at the 2021 American Academy of Neurology meeting (AAN) meeting.
